December 1, 2015
Recently presented data showed patients with Raynaud’s syndrome treated with phosphodiesterase-5 inhibitors had reduced frequency and duration of disease flares, which were also less painful following treatment.
Using the Cochrane Library, MEDLINE, EMBASE and ClinicalTrials.gov to identify randomized controlled trials, researchers examined data from 255 patients with Raynaud’s syndrome treated with either phosphodiesterase-5 inhibitors or placebo. Of these patients, 97% had the disease secondary to systemic sclerosis. The studies included four trials with tadalafil, two trials with sildenafil and one trial with vardenafil. Characteristics identified included frequency, duration and severity of attacks and pain, Patient Global Scale score, withdrawals and serious adverse events, which investigators analyzed with fixed effects models, standardized mean differences or pooled risk ratios.